

SUPPLEMENTARY TABLES

Altered plasma, urine, and tissue profiles of sulfatides and sphingomyelins in patients with renal cell carcinoma

Robert Jirásko^{1*}, Jakub Idkowiak¹, Denise Wolrab¹, Aleš Kvasnička², David Friedecký², Krzysztof Polański³, Hana Študentová⁴, Vladimír Študent⁵, Bohuslav Melichar⁴ and Michal Holčapek¹

¹Department of Analytical Chemistry, Faculty of Chemical Technology, University of Pardubice,
Studentská 573, 53210 Pardubice, Czech Republic

²Laboratory for Inherited Metabolic Disorders, Faculty of Medicine and Dentistry, Palacký University
and Department of Clinical Biochemistry, University Hospital Olomouc, 779 00 Olomouc, Czech
Republic

³Wellcome Sanger Inst, Wellcome Genome Campus, Cambridge, England

⁴Department of Oncology, Faculty of Medicine and Dentistry, Palacký University and
University Hospital, Olomouc, Czech Republic

⁵Department of Urology, Faculty of Medicine and Dentistry, Palacký University and
University Hospital, Olomouc, Czech Republic

*Corresponding author:

Robert Jirásko, Ph.D., Department of Analytical Chemistry, Faculty of Chemical Technology,
University of Pardubice, Studentská 573, 53210 Pardubice, Czech Republic, e-mail:
robert.jirasko@upce.cz, phone: +420 466 037 089, fax: +420 466 037 068

Table 1 Abbreviation of the sterols observed in urine samples with theoretical m/z value, elemental composition, and suggestion of the most probable corresponding compounds for individual elemental compositions.

Abbreviation	Theoretical m/z of [M-H] ⁻	Elemental composition	Suggested compound
StS 1	411.1847	C ₂₁ H ₃₂ O ₆ S	tetrahydrocorticosterone sulfate -H ₂ O
StS 2	429.1953	C ₂₁ H ₃₄ O ₇ S	tetrahydrocorticosterone sulfate
StS 3	441.1589	C ₂₁ H ₃₀ O ₈ S	cortisol sulfate
StS 4	445.1902	C ₂₁ H ₃₄ O ₈ S	tetrahydrocortisol sulfate
StS 5	455.2473	C ₂₄ H ₄₀ O ₆ S	lithocholic acid sulfate
StS 6	465.304	C ₂₇ H ₄₆ O ₄ S	cholesterol sulfate
StS 7	471.2422	C ₂₄ H ₄₀ O ₇ S	ursodeoxycholic acid sulfate
StS 8	482.2946	C ₂₆ H ₄₅ NO ₅ S	taurolithocholic acid
StS 9	487.2371	C ₂₄ H ₄₀ O ₈ S	sulfocholic acid
StS 10	498.2895	C ₂₆ H ₄₅ NO ₆ S	taurodeoxycholic acid
StS 11	512.2688	C ₂₆ H ₄₃ NO ₇ S	sulfoglycolithocholic acid
StS 12	514.2844	C ₂₆ H ₄₅ NO ₇ S	taurocholic acid
StS 13	528.2637	C ₂₆ H ₄₃ NO ₈ S	glycochenodeoxycholic acid sulfate

Table 2 Spearman correlation heatmap showing values of positive (red) and negative (blue) correlations between individual lipids studied and age in plasma samples from controls (N), patients with tumor stage T1-2, and patients with tumor stage T3-4, separately shown for males and females. For values in bold FDR < 0.05, and stronger saturation reflects higher association.

		Females			Males		
		N	T1-2	T3-4	N	T1-2	T3-4
Age	SM 32:1;O2	0.03	-0.05	0.08	-0.08	0.11	0.45
Age	SM 33:1;O2	-0.09	0.01	0.25	-0.06	0.19	0.32
Age	SM 34:2;O2	0.43	0.17	0.32	0.29	0.09	0.21
Age	SM 34:1;O2	-0.21	0.14	0.33	0.00	0.39	0.30
Age	SM 34:0;O2	-0.22	-0.08	-0.13	0.00	0.24	0.25
Age	SM 35:1;O2	-0.05	-0.16	-0.18	-0.17	0.27	0.35
Age	SM 36:2;O2	0.40	0.10	0.50	0.19	0.00	0.09
Age	SM 36:1;O2	0.08	-0.17	0.30	0.01	0.06	-0.06
Age	SM 36:0;O2	0.20	-0.06	-0.10	-0.04	-0.06	-0.04
Age	SM 37:1;O2	0.04	-0.19	-0.13	-0.10	0.00	0.14
Age	SM 38:2;O2	0.29	0.10	0.18	0.27	-0.04	-0.02
Age	SM 38:1;O2	-0.14	0.07	-0.40	-0.05	-0.22	-0.09
Age	SM 39:1;O2	-0.02	0.11	-0.33	-0.11	-0.16	0.09
Age	SM 40:2;O2	0.27	-0.04	-0.03	0.06	-0.27	0.06
Age	SM 40:1;O2	-0.25	-0.02	-0.63	-0.12	-0.38	-0.24
Age	SM 41:2;O2	0.18	0.11	-0.17	0.04	-0.11	0.31
Age	SM 41:1;O2	-0.15	0.07	-0.37	-0.20	-0.27	-0.02
Age	SM 42:3;O2	0.22	0.06	0.17	0.12	-0.01	-0.07
Age	SM 42:2;O2	0.04	0.00	-0.40	0.04	-0.04	-0.36
Age	SM 42:1;O2	-0.24	-0.07	-0.50	-0.24	-0.36	-0.25
Age	SM 43:2;O2	0.23	-0.02	-0.25	0.00	0.11	0.06
Age	SHexCer 34:1;O2	0.28	-0.04	0.80	0.06	0.19	0.42
Age	SHexCer 34:1;O3	-0.30	0.13	0.17	0.01	0.11	0.27
Age	SHexCer 40:1;O2	0.26	-0.01	-0.72	-0.02	-0.05	-0.02
Age	SHexCer 40:2;O3	0.12	0.05	-0.15	0.04	-0.07	-0.09
Age	SHexCer 40:1;O3	-0.07	-0.22	-0.23	-0.14	-0.32	-0.07
Age	SHexCer 42:3;O2	-0.13	0.14	-0.02	0.02	0.09	-0.43
Age	SHexCer 42:2;O2	-0.07	0.27	-0.52	-0.08	0.17	-0.28
Age	SHexCer 42:1;O2	0.11	0.02	-0.55	0.02	0.08	-0.26
Age	SHexCer 41:1;O3	0.02	-0.37	-0.40	-0.17	-0.26	0.06
Age	SHexCer 42:3;O3	0.20	0.10	-0.12	0.03	0.00	-0.14
Age	SHexCer 42:2;O3	0.02	0.02	-0.03	0.05	-0.23	-0.26
Age	SHexCer 42:1;O3	-0.08	0.00	-0.27	0.01	-0.41	-0.04

Table 3 Spearman correlation heatmap showing values of positive (red) and negative (blue) correlations between individual lipids studied and BMI in plasma samples from controls (N), patients with tumor stage T1-2, and patients with tumor stage T3-4, shown separately for males and females. For values in bold FDR < 0.05, and stronger saturation reflects higher association.

		Females			Males		
		N	T1-2	T3-4	N	T1-2	T3-4
BMI	SM 32:1;O2	0.08	-0.02	0.69	0.03	-0.03	0.02
BMI	SM 33:1;O2	0.00	-0.37	0.50	-0.23	0.01	0.02
BMI	SM 34:2;O2	0.28	0.52	0.64	-0.06	0.07	0.20
BMI	SM 34:1;O2	-0.25	-0.39	-0.40	-0.32	-0.31	-0.32
BMI	SM 34:0;O2	-0.18	-0.30	-0.52	0.07	-0.05	0.09
BMI	SM 35:1;O2	0.11	-0.26	0.17	0.05	-0.12	0.18
BMI	SM 36:2;O2	0.34	0.52	0.48	0.19	0.29	0.23
BMI	SM 36:1;O2	0.22	0.31	-0.21	0.47	0.39	0.07
BMI	SM 36:0;O2	0.44	0.39	-0.12	0.44	0.32	0.05
BMI	SM 37:1;O2	0.37	-0.11	0.33	0.36	0.11	0.03
BMI	SM 38:2;O2	0.22	0.32	0.43	0.02	0.20	0.29
BMI	SM 38:1;O2	0.10	-0.10	0.52	0.36	0.43	0.24
BMI	SM 39:1;O2	0.15	-0.25	0.67	0.13	0.20	0.31
BMI	SM 40:2;O2	0.15	0.39	0.48	0.03	0.06	0.10
BMI	SM 40:1;O2	0.11	0.13	0.14	0.36	0.33	0.35
BMI	SM 41:2;O2	0.04	-0.21	0.76	-0.12	-0.15	0.13
BMI	SM 41:1;O2	0.08	-0.16	0.64	0.17	0.22	0.44
BMI	SM 42:3;O2	0.05	0.33	0.19	-0.24	-0.30	0.00
BMI	SM 42:2;O2	-0.11	-0.08	-0.60	-0.15	-0.21	-0.35
BMI	SM 42:1;O2	0.03	0.02	0.07	0.20	0.10	0.30
BMI	SM 43:2;O2	0.12	-0.40	-0.14	-0.01	-0.13	-0.21
BMI	SHexCer 34:1;O2	0.11	0.08	0.31	0.11	0.22	0.01
BMI	SHexCer 34:1;O3	-0.07	0.18	-0.10	-0.03	0.17	0.07
BMI	SHexCer 40:1;O2	0.19	-0.01	0.17	0.06	-0.11	0.39
BMI	SHexCer 40:2;O3	0.13	0.06	-0.10	-0.22	-0.10	0.05
BMI	SHexCer 40:1;O3	0.27	0.16	0.74	0.19	0.21	0.27
BMI	SHexCer 42:3;O2	-0.40	-0.01	-0.60	-0.46	-0.37	-0.15
BMI	SHexCer 42:2;O2	-0.43	-0.30	-0.67	-0.39	-0.54	-0.33
BMI	SHexCer 42:1;O2	-0.25	-0.25	-0.64	-0.14	-0.31	0.14
BMI	SHexCer 41:1;O3	0.12	-0.46	0.48	-0.05	-0.18	0.15
BMI	SHexCer 42:3;O3	0.07	-0.13	-0.57	-0.24	-0.19	-0.05
BMI	SHexCer 42:2;O3	0.11	0.27	0.69	-0.03	0.07	-0.12
BMI	SHexCer 42:1;O3	0.13	-0.18	0.57	0.31	0.28	0.28

Table 4 List of concentrations of individual internal standards used for the analytical validation experiments in plasma and urine samples for low (LL), medium (ML), and high (HL) concentration levels.

	c [nmol/ml of plasma]		
	LL	ML	HL
SM 18:1;O2/12:0	21.65	43.3	64.95
SHexCer 18:1;O2/12:0	0.05	0.1	0.15
c [nmol/ml of urine]			
	LL	ML	HL
Taurocholic acid D4	0.183	0.55	1.65
SHexCer 18:1;O2/12:0	0.013	0.04	0.12

Table 5 Median of absolute intensities and individual coefficients of variation (CV) for each IS - calculated from 5 repetitions (consecutive measurements) within individual samples of the plasma validation experiment. Data have been used to calculate recovery rates ($x = \text{IS added before the extraction}$ and $y = \text{IS added after extraction}$) and precisions (x). The individual CV values represent repeatability.

IS addition	Day	Level	SM 30:1;O2		SHexCer 30:1;O2	
			Median of Intensity	CV [%]	Median of Intensity	CV [%]
Low level (IS added before extraction)	1 st day	Lx1	8.25E+05	7	1.00E+05	19
		Lx2	7.62E+05	5	8.94E+04	12
		Lx3	7.57E+05	8	8.15E+04	14
		Lx4	7.76E+05	7	1.05E+05	4
	2 nd day	Lx5	8.20E+05	7	9.94E+04	6
		Lx6	8.29E+05	14	1.04E+05	4
		Ly1	7.83E+05	10	7.72E+04	11
		Ly2	7.45E+05	14	7.36E+04	10
Low level (IS added after extraction)	1 st day	Ly3	7.65E+05	12	6.74E+04	12
		Ly4	8.59E+05	8	1.03E+05	5
		Ly5	9.05E+05	4	7.98E+04	2
		Ly6	8.27E+05	7	9.78E+04	9
	2 nd day	Mx1	1.09E+06	5	1.12E+05	16
		Mx2	9.78E+05	14	1.15E+05	10
		Mx3	1.05E+06	8	1.14E+05	2
		Mx4	9.10E+05	5	1.34E+05	8
Medium level (IS added before extraction)	1 st day	Mx5	1.13E+06	9	1.36E+05	10
		Mx6	1.03E+06	4	1.38E+05	8
		My1	1.09E+06	10	9.04E+04	5
		My2	1.04E+06	10	9.92E+04	11
	2 nd day	My3	9.07E+05	7	9.96E+04	10
		My4	1.07E+06	7	1.40E+05	7
		My5	1.08E+06	8	1.42E+05	9
		My6	1.08E+06	5	1.27E+05	9
High level (IS added before extraction)	1 st day	Hx1	1.67E+06	6	2.19E+05	5
		Hx2	2.06E+06	14	2.32E+05	9
		Hx3	1.76E+06	17	2.28E+05	16
		Hx4	1.71E+06	11	2.44E+05	5
	2 nd day	Hx5	1.91E+06	19	2.42E+05	9
		Hx6	1.77E+06	6	2.36E+05	9
		Hy1	1.92E+06	18	1.97E+05	17
		Hy2	1.78E+06	12	1.99E+05	7
High level (IS added after extraction)	1 st day	Hy3	1.90E+06	12	2.00E+05	20
		Hy4	1.90E+06	7	2.05E+05	5
		Hy5	1.86E+06	10	2.36E+05	14
	2 nd day	Hy6	1.92E+06	10	2.52E+05	6

Table 6 Median of absolute intensities and individual coefficients of variation (CV) for each IS - calculated from 5 repetitions (consecutive measurements) within individual samples of plasma validation experiments. Data obtained for samples "before freeze/thaw" were used for matrix effect evaluation at three concentration levels. The freeze/thaw stability was evaluated based on the three freeze/thaw cycles for the medium concentration level. The individual CV values represent repeatability.

Concentration level	Cyclus	Sample No.	SM 30:1;O2		SHexCer 30:1;O2	
			Median of Intensity	CV [%]	Median of Intensity	CV [%]
Low level	before freeze/thaw	L_31	9.08E+05	3	9.42E+04	9
		L_43	8.57E+05	8	8.69E+04	11
		L_96	8.00E+05	7	8.26E+04	9
		L_97	9.50E+05	12	8.15E+04	8
		L_101	1.17E+06	18	8.78E+04	5
		L_107	9.13E+05	6	7.09E+04	13
High level	before freeze/thaw	H_31	1.81E+06	9	2.24E+05	2
		H_43	1.66E+06	6	1.68E+05	11
		H_96	1.51E+06	8	1.67E+05	4
		H_97	1.94E+06	6	1.82E+05	17
		H_101	2.49E+06	9	2.28E+05	8
		H_107	2.03E+06	5	1.99E+05	6
	before freeze/thaw	M_31	1.35E+06	4	1.34E+05	7
		M_43	1.01E+06	5	1.06E+05	9
		M_96	1.04E+06	11	1.05E+05	13
		M_97	1.02E+06	9	1.08E+05	16
		M_101	1.40E+06	11	1.11E+05	3
		M_107	1.14E+06	5	8.73E+04	5
Medium level	1 st freeze/thaw cyclus	M_31	1.03E+06	8	9.81E+04	3
		M_43	8.94E+05	8	9.35E+04	17
		M_96	8.52E+05	9	8.43E+04	3
		M_97	8.49E+05	12	8.38E+04	14
		M_101	1.14E+06	10	8.62E+04	6
		M_107	1.29E+06	9	9.62E+04	21
	2 nd freeze/thaw cyclus	M_31	8.81E+05	18	8.92E+04	14
		M_43	8.96E+05	10	7.19E+04	22
		M_96	1.10E+06	6	1.09E+05	14
		M_97	9.27E+05	7	8.61E+04	16
		M_101	1.09E+06	9	7.96E+04	23
		M_107	1.17E+06	9	1.04E+05	23
3 rd freeze/thaw cyclus	3 rd freeze/thaw cyclus	M_31	8.83E+05	5	8.98E+04	10
		M_43	1.33E+06	13	1.42E+05	8
		M_96	8.63E+05	4	7.86E+04	11
		M_97	7.78E+05	11	6.87E+04	20
		M_101	1.03E+06	3	5.67E+04	18
		M_107	8.44E+05	7	6.88E+04	10

Table 7 Median of absolute intensities and individual coefficients of variation (CV) for IS used in the case of urine samples - calculated from 5 repetitions within the individual sample type of urine validation experiment. Data have been used for the calculation of recovery rates (x = IS added before the extraction) and y = IS added after extraction), precisions (x), and freeze/thaw stability. The individual CV values represent repeatability.

Concentration level (IS addition)	Day	Level	SHexCer 30:1;O2		Taurocholic acid-d4	
			Median of Intensity	CV [%]	Median of Intensity	CV [%]
Low level (IS added before extraction)	1 st day	Lx1	2.72E+04	16	1.84E+04	4
		Lx2	2.43E+04	24	1.64E+04	7
		Lx3	3.42E+04	12	1.28E+04	3
		Lx4	2.67E+04	21	1.81E+04	22
	2 nd day	Lx5	2.57E+04	14	1.98E+04	21
		Lx6	1.55E+04	23	9.80E+03	34
		Ly1	3.20E+04	10	1.55E+04	7
		Ly2	2.88E+04	13	1.74E+04	8
Low level (IS added after extraction)	1 st day	Ly3	3.50E+04	14	1.49E+04	11
		Mx1	1.06E+05	9	6.60E+04	3
		Mx2	7.54E+04	15	5.38E+04	16
	1 st day	Mx3	9.22E+04	12	7.86E+04	3
		My1	1.01E+05	19	7.64E+04	11
		My2	9.10E+04	9	5.51E+04	12
Medium level (IS added before extraction)	1 st day	My3	9.89E+04	13	6.55E+04	8
		Hx1	4.83E+05	19	3.15E+05	2
		Hx2	5.52E+05	5	3.03E+05	4
		Hx3	4.73E+05	15	2.98E+05	11
	2 nd day	Hx4	5.05E+05	16	2.71E+05	13
		Hx5	5.44E+05	13	2.46E+05	10
		Hx6	5.11E+05	11	3.28E+05	14
		Hy1	3.87E+05	12	2.40E+05	13
High level (IS added after extraction)	1 st day	Hy2	3.37E+05	12	1.97E+05	5
		Hy3	3.72E+05	21	2.78E+05	5
		Lx4	3.25E+04	20	1.30E+04	16
	3 rd day	Lx5	2.74E+04	24	1.29E+04	12
		Lx6	1.75E+04	33	9.91E+03	30
		Hx4	3.42E+05	15	1.82E+05	10
freeze/thaw cyclus	3 rd day	Hx5	3.48E+05	14	2.20E+05	5
		Hx6	2.80E+05	11	2.55E+05	6

Table 8 Raw IS intensities and individual coefficients of variation (n=5) used for calibration curves - for plasma (upper part of the table) and urine samples (bottom part of the table).

SM 30:1;O2			SHexCer 30:1;O2		
c [nmol/mL]	Median of Intensity	CV[%]	c [pmol/mL]	Median of Intensity	CV [%]
8.66	2.80E+05	6	20	2.23E+04	5
17.32	6.35E+05	17	40	6.67E+04	15
25.99	8.90E+05	8	60	9.26E+04	3
34.65	1.09E+06	11	80	1.17E+05	5
43.31	1.50E+06	5	100	1.56E+05	8
51.97	1.67E+06	6	120	1.95E+05	4
69.3	2.28E+06	6	160	2.66E+05	7
86.62	3.11E+06	10	200	3.44E+05	9

SHexCer 30:1;O2			Taurocholic acid-d4		
c [pmol/mL]	Median of Intensity	CV [%]	c [nmol/mL]	Median of Intensity	CV [%]
2.25	1.13E+04	13	0.12	1.65E+04	10
4.50	4.29E+04	20	0.25	5.84E+04	7
8.99	6.93E+04	10	0.62	9.73E+04	11
22.49	1.38E+05	11	1.23	2.38E+05	5
44.97	3.35E+05	10	2.46	5.80E+05	6
89.94	8.95E+05	4	6.15	1.22E+06	5
224.85	1.53E+06	6	12.30	2.27E+06	5
449.71	3.45E+06	9	24.61	5.77E+06	7

Table 9 Individual recovery rates calculated based on the raw data in Supplementary Table 5 together with average values and coefficients of variation obtained for the extraction protocol of pooled plasma sample for applied internal standards, where abbreviation LL means low concentration level, ML means medium concentration level, and HL means high concentration level.

Level	Sample No.	Recovery rate [%]	
		SM 30:1;O2	SHexCer 30:1;O2
Low level	LL1	105	130
	LL2	102	121
	LL3	99	121
	LL4	90	101
	LL5	91	125
	LL6	100	107
	Average	98	118
Medium level	CV [%]	6	9
	ML1	100	124
	ML2	94	116
	ML3	115	114
	ML4	85	96
	ML5	105	96
	ML6	95	109
High level	Average	99	109
	CV [%]	10	10
	HL1	87	111
	HL2	115	116
	HL3	93	114
High level	HL4	90	119
	HL5	103	103
	HL6	92	94
	Average	97	109
	CV [%]	10	8

Table 10 Individual recovery rates calculated based on the raw data in Supplementary Table 7 together with average values and coefficients of variation obtained for the extraction protocol of the pooled urine sample for applied internal standards, where abbreviation LL means low concentration level, ML means medium concentration level, and HL means high concentration level.

Level	Sample No.	Recovery rate [%]	
		SHexCer 30:1;O2	Taurocholic acid-d4
Low level	LL1	85	119
	LL2	84	106
	LL3	98	83
	Average	89	102
	CV [%]	6	15
	ML1	105	101
Medium level	ML2	83	98
	ML3	93	120
	Average	94	106
	CV [%]	9	10
	HL1	96	116
High level	HL2	111	123
	HL3	93	91
	Average	100	110
	CV [%]	8	14

Table 11 Coefficients of variation representing within (n=3) and between (n=6) days precision for internal standards applied for plasma measurements (upper part of the table) and urine measurements (bottom part of the table). Individual verage intensities and CV were calculated from the absolute intensities of Supplementary Tables 5 (plasma) and 7 (urine). The abbreviation LL means low concentration level, ML means medium concentration level and HL means high concentration level.

Type	Level	SM 30:1;O2		SHexCer 30:1;O2	
		Average Intensity	CV [%]	Average Intensity	CV [%]
Within day precision	LL	7.81E+05	4	9.04E+04	9
	ML	1.04E+06	4	1.14E+05	1
	HL	1.83E+06	9	2.26E+05	2
Between day precision	LL	7.95E+05	4	9.66E+04	9
	ML	1.03E+06	7	1.25E+05	9
	HL	1.80E+06	7	2.41E+05	4

Type	Level	SM 30:1;O2		SHexCer 30:1;O2	
		Average Intensity	CV [%]	Average Intensity	CV [%]
Within day precision	LL	2.86E+04	15	1.59E+04	14.6
	HL	5.03E+05	7	3.05E+05	2.3
Between day precision	LL	2.56E+04	22	1.59E+04	22.0
	HL	4.34E+05	17	2.72E+05	15.1

Table 12 Matrix effect of internal standards used for plasma measurements. The matrix effect is expressed by the coefficient of variation of average signal response within 6 different plasma samples (individual raw intensities are shown in Supplementary Table 6) at three concentration levels, where the abbreviation LL means low concentration level, ML means medium concentration level, and HL means high concentration level.

Level	SM 30:1;O2		SHexCer 30:1;O2	
	Average Intensity	CV [%]	Average Intensity	CV [%]
LL	9.33E+05	12	8.40E+04	9
ML	1.16E+06	14	1.08E+05	13
HL	1.91E+06	16	1.95E+05	13

Table 13 The upper part of the table shows the freeze/thaw stability of internal standards at medium concentration level applied for plasma measurements. Freeze/thaw stability is expressed by the coefficient of variation of the average signal response for 6 individual plasma samples after 3 freeze/thaw cycles (individual raw intensities are shown in Supplementary Table 6). The bottom part of the table shows freeze/thaw stability of internal standards applied for urine measurements. The freeze/thaw stability is expressed by the coefficient of variation (n=3) of average signal response for the pooled sample at a low (LL) and high (HL) concentration levels after one freeze/thaw cycle (individual absolute intensities of LL4 – LL6 and HL4 – HL6 before and after freeze/thaw cycle are shown in Supplementary Table 8).

Sample		SM 30:1;O2		SHexCer 30:1;O2	
No	Average Intensity	CV [%]	Average Intensity	CV [%]	
M_31	1.04E+06	18	1.03E+05	18	
M_43	1.03E+06	17	1.03E+05	25	
M_96	9.65E+05	11	9.41E+04	14	
M_97	8.93E+05	10	8.66E+04	16	
M_101	1.17E+06	12	8.35E+04	23	

Level	Taurocholic acid-d4		SHexCer 30:1;O2	
	Average Intensity	CV [%]	Average Intensity	CV [%]
LL	1.39E+04	27	2.42E+04	24.4
HL	2.29E+05	14.5	3.44E+05	9.8